Session » Sjögren's Syndrome Poster I: Translational Research

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 571

Anti-Modified Protein Antibody Response Pattern in Primary Sjögren’s Syndrome: Clinical and Prognostic Implications

9:00AM-11:00AM: Abstract Number: 562

Anti-Muscarinic Receptor 3 Antibodies – a Cross Reactive Result of Ro60 Immunization

9:00AM-11:00AM: Abstract Number: 572

Biopsy Accuracy in Sjögren’s Syndrome: Analysis of 803 Patients Presenting with Sicca Syndrome Referred to Labial Salivary Gland Biopsy

9:00AM-11:00AM: Abstract Number: 560

Clinical Relevance of Serum Free Light Chain Level As Biomarker in Primary Sjögren′s Syndrome

9:00AM-11:00AM: Abstract Number: 568

Complement Consumption As a Predictor of Pulmonary Manifestation in Patients with Primary Sjögren’s Syndrome: Results from a Unicentric Observational Study

9:00AM-11:00AM: Abstract Number: 561

Comprehensive Immuno-Phenotyping of Follicular Helper T Cell and B Cell Subpopulations in Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 553

Decreased Circulating CXCR3+CCR9+ Th Cells Coincides with Elevated Levels of Their Ligands CXCL10 and CCL25 in the Salivary Gland of Sjögren’s Syndrome Patients Which Synergistically Facilitate Th Cell Migration

9:00AM-11:00AM: Abstract Number: 575

Distinct Clinical and Immunological Features of Anti-Centromere Antibody Positive Primary Sjögren’s Syndrome: A Single Center Cross-Sectional Cohort Study

9:00AM-11:00AM: Abstract Number: 557

Enhanced Expression of NLRP3 Inflammasome-Related Inflammation in Peripheral Blood Mononuclear Cells in Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 565

Fatigue in Primary Sjögren’s Syndrome (pSS) Is Associated with Lower Levels of Proinflammatory Cytokines: A Validation Study

9:00AM-11:00AM: Abstract Number: 556

Identification and Validation of S100 Salivary Proteins As Putative Biomarkers for Different Subsets of Primary Sjögren’s Syndrome Patients

9:00AM-11:00AM: Abstract Number: 566

Immune Response to Seasonal Flu Vaccination in Patients with Primary Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 576

Immunosignature-Based Diagnosis and Prediction of Therapeutic Response Enables Retrospective Patient Stratification in a Phase IIa Clinical Trial for VAY736 in Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 574

Is Elastography a New Tool to Differentiate Sjögren Syndrome to Sicca Syndrome?: Results of the Elsa (elastography of salivary glands) Study

9:00AM-11:00AM: Abstract Number: 569

Is the Oral Microbiome Involved in the Pathogenesis of Sjogren’s Syndrome?

9:00AM-11:00AM: Abstract Number: 552

Mast Cells Are Involved in the Pathogenesis of Sjögren Syndrome By Inducing Tissue Fibrosis

9:00AM-11:00AM: Abstract Number: 567

Minor Salivary Gland Histopathology, Major Salivary Gland Ultrasonography, and Secretory Function in Smoking Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 564

Molecular Identification of a Ro-Specific Salivary IgA Repertoire with Unique Clonal Signatures in Primary Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 559

Performance of Multiple Platforms for Autoantibody Testing in Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 554

Prognostic Significance of Double Positive Anti Ro/SS-a and La/SS-B Antibodies in Patients with Primary Sjogren’s Syndrome: Prospective Salivary Gland Ultrasound Study

9:00AM-11:00AM: Abstract Number: 558

Salivary Syndecan-1 Levels Are Associated with Salivary Gland Dysfunction and Immune Dysregulation in Patients with Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 570

Signalling Pathways Identified in Salivary Glands from Primary Sjögren’s Syndrome Patients Reveal Enhanced Adipose Tissue Development, As Demonstrated By Microarray Analysis, Real-Time PCR and Immunohistochemistry

9:00AM-11:00AM: Abstract Number: 573

Subepithelial Infiltrate of the Vagina in Primary Sjogren’s Syndrome: The Cause of Vaginal Dryness?

9:00AM-11:00AM: Abstract Number: 555

The Corrected QT(QTc) Interval Is Associated with Myocardial Fibrosis in Primary Sjögren Syndrome, Assessed By a Cardiac Magnetic Resonance Approach: A Prospective Pilot Study at a Single Center

9:00AM-11:00AM: Abstract Number: 563

The Effect of Non-Invasive Vagus Nerve Stimulation on Fatigue and Immune Responses in Patients with Primary Sjögren’s Syndrome

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].